Montoya A, Mawulawde K, Houck J, Sullivan H, Lonchyna V, Blakeman B, Hinkamp T, Garrity E, Pifarre R
Department of Thoracic and Cardiovascular Surgery, Loyola University Medical Center, Maywood, IL 60153.
Surgery. 1994 Oct;116(4):712-8.
The experience at Loyola University Chicago was retrospectively reviewed to evaluate survival and functional outcome after single lung transplantation (SLT) and bilateral lung transplantation (BLT).
Ninety patients underwent lung transplantation at Loyola University Chicago between April 1990 and December 1993. Mean age was 45 years (range, 13 to 66 years). Fifty percent were male. Pre-lung transplant pulmonary diseases were as follows: emphysema and/or chronic obstructive pulmonary disease in 43 patients, pulmonary fibrosis in 13, cystic fibrosis in 14, pulmonary hypertension in eight, repeated transplantation for obliterative bronchiolitis in four, bronchiectasis in two, bronchoalveolar cell carcinoma in two, sarcoidosis in one, primary obliterative bronchiolitis in one, histiocytosis X in one, and lymphangiomyomatosis in one. Fifty-seven patients underwent SLT, and 33 had BLT. Maintenance immunosuppression medications consisted of cyclosporine, azathioprine, and prednisone.
Perioperative complications were as follows: seven of 33 patients bled after BLT, and two of 57 bled after SLT. Bronchial complications were found in six of 66 (9%) BLT anastomoses and eight of 57 (14%) SLT anastomoses. Nine operative deaths occurred in SLT patients: six from allograft failure, one from infection, one from intrapulmonary hemorrhage, and one from bronchial dehiscence. Only two patients died in the perioperative period after BLT and that was of infection. Three late deaths occurred after BLT, all as a result of infection; 13 recipients died late after SLT: five of infection, four patients from lymphoma, two of pancreatitis, one of tension pneumothorax, and one of pulmonary embolism. For the entire patient population the actuarial 1- and 2-year survival rates were 72% and 68%, respectively. One-year survival rates were significantly better for patients undergoing lung transplantation for obstructive and nonrestrictive lung diseases than those of patients undergoing lung transplantation for vascular or restrictive pulmonary disease. Recipients of BLT had a trend toward better survival than recipients of SLT. Lung function 6 months after transplantation measured by forced expiratory volume in 1 second was significantly better in BLT than SLT, 71% of predicted versus 54%.
Patients who undergo BLT have significantly better postoperative pulmonary function than those who undergo SLT. On the basis of the study there was a trend toward better survival with BLT.
回顾性分析了芝加哥洛约拉大学的经验,以评估单肺移植(SLT)和双肺移植(BLT)后的生存率和功能结局。
1990年4月至1993年12月期间,90例患者在芝加哥洛约拉大学接受了肺移植。平均年龄为45岁(范围13至66岁)。50%为男性。肺移植前的肺部疾病如下:43例患者患有肺气肿和/或慢性阻塞性肺疾病,13例患有肺纤维化,14例患有囊性纤维化,8例患有肺动脉高压,4例因闭塞性细支气管炎接受再次移植,2例患有支气管扩张,2例患有支气管肺泡细胞癌,1例患有结节病,1例患有原发性闭塞性细支气管炎,1例患有组织细胞增多症X,1例患有淋巴管平滑肌瘤病。57例患者接受了单肺移植,33例接受了双肺移植。维持性免疫抑制药物包括环孢素、硫唑嘌呤和泼尼松。
围手术期并发症如下:33例双肺移植患者中有7例术后出血,57例单肺移植患者中有2例术后出血。66例双肺移植吻合口中有6例(9%)发生支气管并发症,57例单肺移植吻合口中有8例(14%)发生支气管并发症。单肺移植患者中有9例手术死亡:6例死于移植失败,1例死于感染,1例死于肺内出血,1例死于支气管裂开。双肺移植患者围手术期仅2例死亡,均死于感染。双肺移植后有3例晚期死亡,均为感染所致;单肺移植后有13例受者晚期死亡:5例死于感染,4例死于淋巴瘤,2例死于胰腺炎,1例死于张力性气胸,1例死于肺栓塞。整个患者群体的1年和2年精算生存率分别为72%和68%。因阻塞性和非限制性肺部疾病接受肺移植的患者1年生存率明显高于因血管性或限制性肺部疾病接受肺移植的患者。双肺移植受者的生存率有高于单肺移植受者的趋势。移植后6个月通过第1秒用力呼气量测量的肺功能,双肺移植明显优于单肺移植,分别为预测值的71%和54%。
接受双肺移植的患者术后肺功能明显优于接受单肺移植的患者。基于该研究,双肺移植有生存率更高的趋势。